Group One Trading’s Viridian Therapeutics VRDN Stock Holding History

Group One Trading’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24.6K	Buy	+1,195	New	+$25.5K	﹤0.01%	5735
2026 Q2	–	Sell	-625	Closed	-$10.1K	–	8599
2026 Q1	$12.2K	Buy	625 +396	+173%	+$11.8K	﹤0.01%	6256
2025 Q4	$7.13K	Buy	+229	New	+$6.28K	﹤0.01%	7003
2025 Q1	–	Sell	-47,995	Closed	-$818K	–	8434
2024 Q4	$920K	Buy	47,995 +7,233	+18%	+$157K	﹤0.01%	2647
2024 Q3	$927K	Buy	40,762 +30,898	+313%	+$505K	﹤0.01%	2365
2024 Q2	$128K	Buy	+9,864	New	+$137K	﹤0.01%	3758
2024 Q1	–	Sell	-17	Closed	-$330	–	8030
2023 Q4	$370	Sell	17 -2,628	-99%	-$41.5K	﹤0.01%	7120
2023 Q3	$40.6K	Sell	2,645 -3,817	-59%	-$72.8K	﹤0.01%	5297
2023 Q2	$154K	Buy	+6,462	New	+$166K	﹤0.01%	4205

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Group One Trading's VRDN Position: Q3 2026 in Review

Group One Trading opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 1,195 shares worth $24.6K. The stake represents ﹤0.01% of the portfolio and ranks #5735 among its holdings. This is a return to the name: Group One Trading previously reported a position in VRDN as recently as Q1 2026.

Group One Trading first reported a position in VRDN in Q2 2023 and has held it in 9 quarters since. The position peaked at $927K in Q3 2024. 121 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Group One Trading held 1,195 shares of Viridian Therapeutics worth $24.6K as of Q3 2026.
Viridian Therapeutics was a new Group One Trading position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #5735 holding.
Group One Trading first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 9 quarters since.
Group One Trading's Viridian Therapeutics position peaked at $927K in Q3 2024.
121 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.